Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported that the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock performance was -0.93% in last session and finished the day at $7.42. Traded volume was 3.20million shares in the last session and the … Continue reading Oversold Stocks In News: Halozyme Therapeutics (NASDAQ:HALO), Lumos Networks (NASDAQ:LMOS), Advaxis (NASDAQ:ADXS), Sterling Construction Company (NASDAQ:STRL)